On March 21, the National Medical Insurance Bureau issued the Notice on Effectively Doing a Good Job in The Medical Security Work of the Current Epidemic Prevention and Control. The notice makes it clear that the new crown treatment drugs included in the scope of medical insurance payment will be adjusted in a timely manner, and the new nematvir tablets/ritonavir tablets added in the "Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Ninth Edition)" will be purchased by medical institutions in accordance with the price communicated between the enterprise and the relevant departments, and the medical insurance department will pay according to regulations.
On March 16, paxlovid, a treatment for the new crown virus, arrived at Shanghai Pudong Airport. The image is from General Technology Chinese Medicine.
On February 11, the State Food and Drug Administration conditionally approved the import registration of PAXLOVID. According to Pfizer's official website, PAXLOVID is an oral small molecule new coronavirus treatment drug for the treatment of mild to moderate novel coronavirus pneumonia patients with mild to moderate new coronavirus pneumonia with high risk factors for progression to severe disease, such as patients with high risk factors for severe disease such as advanced age, chronic kidney disease, diabetes, cardiovascular disease, and chronic lung disease. Based on the results of the research novel COVID-19 oral antiviral candidate PAXLOVID study published by Pfizer in 2021, the interim analysis showed that the drug reduced the risk of hospitalization and death in high-risk COVID-19 patients by 89%.
As of now, the price of the drug in China has not been publicly disclosed. According to public information, Pfizer PAXLOVID is priced in the United States: a 5-day course, the U.S. government needs to pay about $530 (about 3367 yuan).
On March 20, according to the official WeChat public account of China Medicine, on March 19, the first batch of new coronavirus treatment drugs PAXLOVID cooperated by China Pharmaceutical and Pfizer has arrived at China Pharmaceutical Daxing Logistics Center, and all goods have been closed-loop management of the whole process of transportation in accordance with import and export related epidemic prevention requirements, and have completed the relevant work such as acceptance and warehousing.
China Pharmaceutical said that at present, the company has received an urgent order for urgent protection of drugs, and all drugs are being quickly transported to the front line of the national fight against the epidemic.
